Kymera Therapeutics
KYMR
About: Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Employees: 218
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
219% more call options, than puts
Call options by funds: $10.1M | Put options by funds: $3.16M
150% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 26
72% more capital invested
Capital invested by funds: $2B [Q1] → $3.44B (+$1.44B) [Q2]
44% more funds holding in top 10
Funds holding in top 10: 9 [Q1] → 13 (+4) [Q2]
35% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 51
22% more funds holding
Funds holding: 172 [Q1] → 210 (+38) [Q2]
8.89% more ownership
Funds ownership: 112.12% [Q1] → 121.01% (+8.89%) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
|
Barclays
Etzer Darout
|
$60
|
Overweight
Initiated
|
17 Sep 2025 |
|
RBC Capital
Brian Abrahams
|
$70
|
Outperform
Initiated
|
16 Sep 2025 |
|
Oppenheimer
Jeff Jones
|
$53
|
Outperform
Maintained
|
27 Jun 2025 |
|
Wells Fargo
Derek Archila
|
$53
|
Overweight
Maintained
|
26 Jun 2025 |
|
HC Wainwright & Co.
Andrew Fein
|
$60
|
Buy
Maintained
|
26 Jun 2025 |
Financial journalist opinion
Based on 4 articles about KYMR published over the past 30 days
